These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33155373)

  • 1. Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study.
    Pathak P; Rimac H; Grishina M; Verma A; Potemkin V
    ChemMedChem; 2021 Mar; 16(5):822-838. PubMed ID: 33155373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
    Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
    Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New 6-nitro-4-substituted quinazoline derivatives targeting epidermal growth factor receptor: design, synthesis and
    Farag AB; Othman AH; El-Ashrey MK; Abbas SE; Elwaie TA
    Future Med Chem; 2024; 16(19):2025-2041. PubMed ID: 39230501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
    Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
    Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
    [No Abstract]   [Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
    Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
    Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents.
    Hao S; Wang JH; Hou L; Liang JW; Yan JH; Niu YF; Li XY; Sun Q; Meng FH
    Bioorg Chem; 2024 Oct; 151():107686. PubMed ID: 39111120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
    Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
    Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
    Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
    Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 4-arylaminoquinazolines bearing
    Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
    Wang Z; Liu L; Dai H; Si X; Zhang L; Li E; Yang Z; Chao G; Zheng J; Ke Y; Lihong S; Zhang Q; Liu H
    Bioorg Med Chem; 2021 Aug; 43():116265. PubMed ID: 34192644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 2-[thio]acetamide linked quinazoline/1,2,4-triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers.
    Abdelkhalek AS; Kothayer H; Soltan MK; Ibrahim SM; Elbaramawi SS
    Arch Pharm (Weinheim); 2024 Jul; 357(7):e2300627. PubMed ID: 38593298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.